Search Results (135)

Background: The integration of neoadjuvant and perioperative chemo-immunotherapy (CT-IO) has significantly reshaped the treatment of resectable non-small-cell lung cancer (NSCLC), improving pathological response and survival outcomes. However, its impact on surgical management—particularly robotic-assisted thoracic surgery (RATS)—remains incompletely defined. This review provides a practical overview of current evidence and technical considerations for robotic lung resection following neoadjuvant chemo-immunotherapy. Methods: A narrative review of the literature was performed, focusing on phase III trials, meta-analyses, and surgical series reporting perioperative, oncological, and technical outcomes of minimally invasive—especially robotic—approaches after neoadjuvant or perioperative chemo-immunotherapy. Results: Randomized trials have established CT-IO as a standard treatment option for selected patients with resectable stage II–III NSCLC—although the specific standard varies according to stage, molecular and PD-L1 status, and regulatory approval—significantly improving pathological complete response and event-free survival. However, immune-related fibrosis, nodal scarring, and altered tissue planes increase surgical complexity and intra-postoperative complications. Available evidence, largely retrospective and derived from selected patient populations treated at experienced centers, suggest that RATS is feasible and safe, offering enhanced visualization and dexterity that may facilitate dissection in challenging post-induction settings. Vascular management and lymph node dissection remain critical technical aspects, and early conversion to open surgery, when required, should be regarded as an appropriate safety strategy rather than a complication. Conclusions: RATS after neoadjuvant chemo-immunotherapy appears feasible and promising in selected patients treated at experienced centers, but current evidence does not yet establish it as the preferred approach for all patients. Careful patient selection, adherence to oncological principles, and surgeon experience are essential. Prospective data are needed to define optimal surgical timing and standardize techniques. Full article

Background/Objectives: Primary hyperparathyroidism (PHPT) is most commonly caused by a single cervical parathyroid adenoma; however, a minority of cases originate from ectopic glands, including intrathoracic localizations. Intrathoracic ectopic parathyroid glands (EPGs) are rare and pose significant diagnostic and therapeutic challenges due to their anatomical variability and overlap with other mediastinal pathologies. Methods: We retrospectively analyzed 13 consecutive patients with PHPT caused by intrathoracic EPGs, who underwent minimally invasive surgical resection between 2015 and 2024 at two Italian tertiary referral centers. Demographic characteristics, biochemical profiles, imaging findings, surgical approaches, intraoperative parathyroid hormone (ioPTH) kinetics, and postoperative outcomes were evaluated. Results: All patients underwent successful resection using video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracoscopic surgery (RATS). Ectopic glands were identified in thymic, mediastinal, retroesophageal, paratracheal, and aortopulmonary locations. Postoperative normalization of calcium, phosphate, and PTH levels confirmed biochemical cure in all patients. No intraoperative complications or 30-day mortality were observed. Higher preoperative PTH levels were associated with longer operative times only in an exploratory, non-significant manner. Conclusions: Intrathoracic EPGs should be suspected in patients with PHPT and negative cervical imaging. Minimally invasive thoracic surgery provides safe and effective treatment with excellent biochemical outcomes. Elevated preoperative PTH levels may reflect increased surgical complexity, a hypothesis that warrants validation in larger cohorts. Full article

Background and Objectives: The recent adoption of RATS (robot-assisted thoracic surgery) alongside VATS (video-assisted thoracoscopic surgery) in minimally invasive thoracic surgery highlights the need for comparative evaluation of both techniques regarding postoperative pain and clinical outcomes. This study compared acute postoperative pain within the first 24 h, as well as postoperative complications, 30-day mortality, and length of hospital and ICU stay. Materials and Methods: A retrospective observational study was conducted including all patients scheduled for VATS or RATS at a tertiary hospital between November 2021 and December 2024. Demographic characteristics, surgical procedures, surgical approach, and pain-related outcomes at 24 h (Numeric Rating Scale [NRS], subjective assessment scale, and rescue analgesia) were obtained from the Acute Pain Unit database of the Department of Anesthesiology. Other variables were collected from the electronic medical record. Results: A total of 148 patients were analyzed, of whom 118 underwent VATS and 30 RATS. Surgical duration was significantly longer in the RATS group (130 vs. 218 min, p < 0.05). No significant differences were observed in NRS scores (2.57 ± 1.06 vs. 2.3 ± 0.79, p = 0.195) or subjective pain assessment (good: 78% vs. 83.3%, p = 0.472). RATS required less rescue analgesia in the unadjusted analysis (30.0% vs. 52.5% in VATS, p = 0.022); however, this association was no longer statistically significant after multivariable adjustment (VATS: OR 2.40, 95% CI 0.93–6.25; p = 0.071). There were no significant differences in postoperative complications (17.8% in VATS vs. 16.7% in RATS, p = 0.85), length of hospital stay (4.9 ± 6.2 days in VATS vs. 3.4 ± 3 days in RATS, p = 0.2), or 30-day mortality (0.8% in VATS vs. 0% in RATS, p = 1). ICU length of stay was longer in the RATS group (0.32 ± 0.78 days in VATS vs. 0.73 ± 1.23 days in RATS, p = 0.024). Conclusions: RATS did not demonstrate superiority over VATS in terms of postoperative pain, patient satisfaction, or clinical outcomes. Full article

Background: In patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant chemo-immunotherapy, pulmonary resection can be technically demanding because of hilar/mediastinal inflammation and fibrosis, potentially limiting the use of minimally invasive surgery (MIS). We report our single-center experience with MIS anatomical lung resections after neoadjuvant chemo-immunotherapy. Methods: We retrospectively collected consecutive NSCLC patients who underwent neoadjuvant chemo-immunotherapy followed by anatomical lung resection with an intended MIS approach at our institution between May 2018 and October 2025. Primary endpoints were feasibility and safety (conversion rate, intraoperative and postoperative complications, need for reoperation, and 30-day mortality). Results: Fifty-two patients were included. Mean age was 65.9 ± 8.6 years; 27 (51.9%) were male. Median Charlson Comorbidity Index was 3 (IQR 2–4). Most patients had clinical stage III disease (IIIA 40.4%, IIIB 30.8%). Conversion to open surgery occurred in 7 cases (13.5%). One intraoperative complication was recorded (1.9%). Anatomical resections were predominantly lobectomies (including combined/extended lobectomies) (88.4%); sleeve resections accounted for 11.5%, and bilobectomy for 7.7%. Postoperative complications occurred in 13 patients (25.0%); reoperation for complications was required in 1 case (1.9%). No deaths were recorded in the dataset. Pathological response showed pCR in 22 patients (42.3%) and MPR in 10 (19.2%). Conclusions: In our experience, minimally invasive anatomical lung resection after neoadjuvant chemo-immunotherapy for NSCLC is feasible, with an acceptable conversion rate and manageable morbidity, and is associated with a substantial rate of pathological response. Careful patient selection and surgical expertise remain essential. Full article

Background/Objectives: Intraoperative molecular imaging (IMI) enables real-time visualization of tumor biology during surgery using fluorescent probes and near-infrared imaging systems. As lung cancer screening increases detection of small and nonpalpable pulmonary nodules, conventional localization and margin assessment techniques remain limited, particularly during minimally invasive surgery. This review summarizes the technical foundations, imaging agents, clinical applications, and future directions of IMI in thoracic oncology. Methods: We performed a narrative review to synthesize current evidence regarding the technical foundations, molecular imaging agents, clinical applications, and future directions of intraoperative molecular imaging in thoracic oncology. Given the multidisciplinary scope of the field, a narrative approach was selected to integrate mechanistic, translational, and clinical evidence rather than to answer a single narrowly defined clinical question. Results: IMI generates dynamic intraoperative contrast based on preferential probe accumulation or activation within malignant tissue. Current approaches include non-specific fluorophores such as indocyanine green, activatable probes targeting tumor-associated proteases or acidic microenvironments, and receptor-targeted agents such as pafolacianine. Across prospective studies and multicenter trials, IMI improved localization of nonpalpable lesions, identified occult synchronous malignancies, and enhanced intraoperative margin assessment, frequently altering surgical management. Phase 2 and 3 studies of folate receptor-targeted imaging demonstrated clinically significant findings in a substantial proportion of patients, including lesions not detected by conventional imaging or palpation. However, performance remains dependent on tumor biology, target expression, lesion depth, and optical constraints. Conclusions: IMI represents an emerging transition from anatomy-guided toward biology-informed thoracic surgery by providing real-time molecular information during resection. Current evidence supports its role as a complementary intraoperative technology that augments conventional imaging and surgical techniques, particularly for small, peripheral, and nonpalpable lesions. Full article

The rapid expansion of video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS) has reshaped thoracic surgical practice over the last two decades, offering reduced perioperative morbidity, shorter hospital stay, and oncological outcomes comparable to conventional thoracotomy in appropriately selected patients. Minimally invasive techniques now account for the majority of anatomical pulmonary resections in many high-volume centers and are being explored, in selected patients at experienced institutions, for increasingly complex procedures. This shift, however, raises a question that has received comparatively little attention: whether reduced trainee exposure to open thoracotomy may, over time, erode open thoracic surgical competence. As minimally invasive approaches become the institutional default, exposure to open surgery is declining, and the skills required to perform complex open resections or to manage intraoperative emergencies may become confined to a diminishing cohort of senior surgeons. In this narrative review, we examine the current boundaries of minimally invasive thoracic surgery, define the clinical scenarios in which open surgery remains indispensable—including bronchoplastic and angioplastic resections, post-induction hostile surgical fields, and unplanned conversion—and consider the implications of the ongoing paradigm shift for training, taking into account the substantial variability of thoracic surgical practice across different regions. We argue that open thoracic surgery is not an obsolete discipline but a foundational competence whose preservation may warrant deliberate attention through structured exposure, simulation, mentorship, and dedicated competence assessment. Throughout, we have sought to distinguish documented trends from reasonable concern and from speculative future risk, and we frame the central issue explicitly as a credible and foreseeable risk rather than a demonstrated decline. Full article

Tumor localization during pulmonary surgery has become increasingly challenging with the earlier detection of smaller and smaller lung nodules. Concomitantly, minimally invasive surgical (MIS) techniques have been increasingly adopted within the field of thoracic surgical oncology. Surgeons face growing challenges not only with locating these small tumors, but also with immediate margin assessment, reduced tactile feedback, and nodal assessment. Intraoperative molecular imaging (IMI) has emerged as a promising adjunct to address these challenges by enabling real-time visualization of malignant tissue during pulmonary resection. In its current form, IMI integrates systemically administered, tumor-targeting near-infrared fluorophores with fluorescence-capable imaging platforms to enhance intraoperative decision-making. Early clinical experiences in thoracic surgery suggest particular utility in the localization of small or nonpalpable pulmonary nodules and for improved margin assessment during MIS. Despite encouraging preliminary data, widespread adoption of IMI remains limited by biologic variability in target expression, optical depth constraints, false-positive fluorescence in inflammatory tissue, and challenges in workflow integration. Applications for nodal evaluation, staging, and longer-term oncologic outcome improvement remain investigational. Addressing these multifaceted barriers will be essential for the translation of IMI from a promising, experimental adjunct to a more broadly implementable surgical technology. This work summarizes the current state of IMI in thoracic surgical oncology, highlighting key translational studies, established and emerging clinical applications, and critical limitations within the current landscape. The authors also outline future directions for the field, including quantitative fluorescence interpretation, standardized reporting, and outcomes-driven clinical trials evaluating margin adequacy, recurrence, staging impact, and cost-effectiveness to support widespread evidence-based implementation. Full article

The adoption of neoadjuvant immune checkpoint inhibitor (ICI)-based chemoimmunotherapy has fundamentally transformed the operative landscape of resectable non-small cell lung cancer (NSCLC). Surgeons are now routinely confronted with ICI-altered tissue planes characterized by hilar fibrosis, vascular friability, and disrupted lymph node architecture. Simultaneously, robotic-assisted thoracic surgery (RATS) has consolidated its position as the dominant minimally invasive platform for pulmonary resection, accounting for the majority of lobectomies and segmentectomies performed at high-volume centers in 2023. Whether RATS confers specific technical advantages in this increasingly complex operative context remains incompletely characterized. We conducted a structured narrative review of published evidence, synthesizing data from randomized controlled trials, prospective cohorts, national registry analyses, and emerging technology reports addressing RATS in the setting of neoadjuvant ICI-based therapy for NSCLC. A systematic literature search was conducted across PubMed and EMBASE using predefined search terms. Available evidence, though largely retrospective and limited by small sample sizes, consistently demonstrates that RATS after neoadjuvant chemoimmunotherapy is technically feasible and oncologically sound, with R0 resection achievable in virtually all cases. The enhanced three-dimensional visualization, tremor filtration, and instrument degrees of freedom afforded by robotic platforms appear particularly advantageous in the setting of dense hilar adhesions and fragile pulmonary vasculature. Lymph node yield, a recognized robotic advantage, is preserved or enhanced despite post-ICI fibrosis. Pooled conversion rates to thoracotomy, derived from post hoc surgical analyses of ICI trial populations rather than trials designed to measure conversion, are higher than for upfront resection; available retrospective single-center data, including one direct RATS-versus-VATS comparison, suggest lower conversion rates with RATS in experienced hands, though this conclusion requires prospective validation. Emerging platform integrations, including combined robotic bronchoscopy and thoracoscopic surgery, single-port systems, and artificial intelligence-assisted anatomical navigation, are poised to further extend the reach of minimally invasive surgery in this challenging clinical scenario. In experienced centers, RATS appears to offer a technically favorable minimally invasive platform for pulmonary resection after neoadjuvant ICI-based therapy, with potential advantages over VATS in managing immunotherapy-altered anatomy; however, this conclusion is derived from retrospective series and should be interpreted cautiously pending prospective comparative data. Prospective multicenter trials with standardized surgical endpoints are urgently needed. Full article

Background: Robotic-assisted bronchoscopy enables precise navigation to peripheral pulmonary lesions and expands minimally invasive diagnostic options in thoracic surgery. At our institution, the ION™ Endoluminal System (Intuitive Surgical, Sunnyvale, CA, USA) was introduced to improve diagnostic accuracy in challenging peripheral targets. It is widely recognized that a defined number of procedures is required to achieve procedural proficiency and optimal clinical outcomes when adopting a novel platform. Therefore, this retrospective single-center study aimed to evaluate the learning curve associated with the implementation of this technology in a thoracic surgery center. Methods: In this retrospective study, all consecutive patients who underwent robotic-assisted bronchoscopies performed using the ION™ Endoluminal System (Intuitive Surgical, Sunnyvale, CA, USA) for the diagnosis of peripheral pulmonary lesions between August 2024 and March 2026 were analyzed. A total of 128 lesions in 89 patients were initially identified. Cases involving marker placement without diagnostic biopsy, as well as procedures not performed by the primary operator, were excluded. After applying exclusion criteria, 109 procedures in 76 patients were included. The mean patient age was 65.4 ± 9.1 years, and 44 patients were female (57.9%). To assess the learning curve, procedures were chronologically divided into three groups: early (cases 1–36), intermediate (37–73), and late (74–109). Outcome measures included procedure time, number of biopsies per lesion, tumor size, and diagnostic yield. Group comparisons were performed using non-parametric and chi-square tests. Procedural learning was assessed by cumulative sum (CUSUM) analysis of procedure time. Results: The overall diagnostic yield was 85.3% (93/109). The diagnostic yield increased over time from 73.0% in the early phase to 83.3% in the intermediate phase and 94.6% in the late phase. The overall comparison was statistically insignificant (χ² p = 0.117); however, there was a significant linear trend across phases, indicating progressive improvement with exposure to the application of this technology. Procedure time decreased significantly from a median of 49.0 min in the early phase to 31.0 min in the intermediate phase and 30.0 min in the late phase (p < 0.001). At the same time, the number of biopsies per lesion increased significantly (p < 0.001). Tumor size did not differ significantly between groups (p = 0.170). Conclusions: Robotic-assisted bronchoscopy demonstrates a clear learning curve, characterized by increasing diagnostic yield and significantly reduced procedure time during the implementation phase. The technique can be effectively integrated into the thoracic surgical diagnostic workflow and represents a valuable addition to minimally invasive diagnostics for peripheral pulmonary lesions. Full article

Thin-slice high-resolution computed tomography (CT) has improved the detection of small pulmonary nodules, increasing the demand for minimally invasive diagnostic and therapeutic resection. While lobectomy with lymph node dissection remains the standard surgical approach for many patients with resectable non-small cell lung cancer, accumulating evidence supports sublobar resection for selected small, peripheral, and ground-glass-dominant lesions when sufficient margins are achievable. In thoracoscopic and robotic surgery, localization of nodules ≤10 mm or lesions located >5 mm from the pleural surface can be challenging, and failure to identify the target may lead to conversion, larger resection than intended, or prolonged operative time. Several localization strategies have been developed, including CT-guided percutaneous wire/coil/dye marking, bronchoscopic dye mapping, and virtual-assisted lung mapping (VAL-MAP), robotic-assisted bronchoscopic dye or fiducial localization, radiofrequency identification microtag systems (Surgical Real-Time FInger Navigation and Detection) that provide real-time depth information, and single-stage intraoperative CT-guided marking and resection in hybrid operating rooms. This review synthesizes representative evidence and published outcome ranges, and compares workflows, marker-to-lesion precision metrics, complication profiles, operational burden, and cost structures. We emphasize the practical contrast between two-stage and single-stage workflows, the access-route differences between transthoracic and transbronchial techniques, and the need to report localization-to-incision “time at risk”. We also present an expert-consensus decision algorithm aimed at facilitating tailored selection of localization strategies for modern minimally invasive thoracic surgery. Full article

Background: Direct comparisons between uniportal robotic-assisted (uRATS) and uniportal video-assisted (uVATS) thoracoscopic anatomical lung resection for non-small cell lung cancer (NSCLC) remain scarce. We compared oncologic radicality and perioperative outcomes between the two uniportal approaches in a single-center contemporaneous cohort. Methods: This retrospective cohort study included 56 consecutive NSCLC patients undergoing uniportal anatomical resection between January 2024 and December 2025 (uRATS, n = 12; uVATS, n = 44). The primary endpoint was oncologic radicality of lymph-node dissection (stations sampled, total nodes, mediastinal sampling, R0 rate). Secondary endpoints included operative time, blood loss, pain, recovery metrics, and a composite textbook outcome. Comparisons used Mann–Whitney U and Fisher’s exact tests. Results: Complete (R0) resection was achieved in all 56 patients. The operating surgeon dissected more lymph nodes in the uRATS group (median 13 vs. 7; p = 0.049), with a trend toward more mediastinal stations sampled (4 vs. 3; p = 0.061). Operative time was longer with uRATS (220 vs. 135 min; p < 0.001), but air-leak duration (0 vs. 2 days; p < 0.001), hospital stay (2 vs. 3 days; p = 0.022), and discharge pain (p = 0.017) all favored uRATS. Textbook outcome was achieved in 83% versus 48% (p = 0.047). Conclusions: In a uniportal-experienced unit, uRATS showed comparable intraoperative oncologic-quality metrics to uVATS with directional perioperative-recovery differences favoring uRATS. Larger multicenter studies with longer follow-up are warranted. Full article

Background/Objectives: major open abdominal surgery remains associated with clinically important postoperative pain, delayed gastrointestinal recovery, opioid exposure, and prolonged length of stay. Intravenous lidocaine infusion (IVLI) has biologically plausible analgesic, anti-hyperalgesic, anti-inflammatory, and opioid-sparing effects, but prior evidence syntheses have often combined open and minimally invasive procedures. This systematic review evaluated evidence for perioperative IVLI in adult patients undergoing major open abdominal surgery. Methods: the review was structured according to PRISMA 2020. The final search was run on 15 January 2026 and covered PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP from database inception to that date, without language restrictions at the search stage. Eligible studies enrolled adults undergoing elective open abdominal surgery and compared systemic IVLI with placebo, usual care, or active epidural analgesic comparators. Primary outcomes were postoperative opioid consumption and pain intensity. Secondary outcomes included gastrointestinal recovery, postoperative ileus, length of hospital stay, postoperative nausea and vomiting, inflammatory/stress biomarkers, and adverse events. Results: ten randomized trials involving 658 participants were included. Placebo/usual-care trials and active-comparator trials were synthesized separately because they address different clinical questions. IVLI generally reduced opioid consumption compared with placebo, with extractable effects including a 55.9 mg reduction in 72 h morphine use in one abdominal surgery trial and a 13.9 mg reduction in 24 h morphine use after radical prostatectomy. Gastrointestinal recovery favored IVLI in most placebo-controlled studies; for example, first flatus occurred 12.5 h earlier and first bowel movement 28.4 h earlier in one trial. Active-comparator trials suggested comparable early dynamic pain outcomes versus thoracic epidural analgesia in selected settings, although opioid consumption findings were less consistent. No serious lidocaine-related toxicity was reported, but the included trials were underpowered to detect rare local anesthetic systemic toxicity events and did not consistently capture subclinical neurologic symptoms such as perioral numbness or visual disturbance. Conclusions: in adult open abdominal surgery, perioperative IVLI may provide opioid-sparing and recovery benefits, particularly when infusion continues beyond the intraoperative period. However, the certainty of evidence remains limited. Full article

Background/Objectives: The minimally invasive posterior deltoid-sparing (MIPDS) approach has been described for glenoid fractures; however, its outcomes for Ideberg type Ib, II, III, IV, and V fractures and the influence of concomitant injuries on functional recovery remain poorly understood. This study aimed to report minimum 2-year functional outcomes of these fracture types treated with the MIPDS approach using mini-plates, and to investigate the effect of concomitant thoracic trauma on clinical outcomes. Methods: Thirty-one patients with operatively treated glenoid fossa fractures were stratified into three groups: isolated glenoid fracture, concomitant thoracic trauma, and concomitant ipsilateral upper extremity fracture. Functional outcomes were assessed using the Constant, UCLA, and DASH scores at a minimum follow-up of 2 years. Results: No postoperative infection or nonunion occurred. Mean union time was 9.4 ± 2.4 weeks. Patients with thoracic trauma demonstrated significantly worse functional outcomes across all three scores compared to both other groups: lower Constant scores (70.9 ± 7.5 vs. 85.5 ± 5.9 and 82.6 ± 11.7; p = 0.012 and p = 0.042), lower UCLA scores (24.6 ± 7.9 vs. 32.5 ± 3.0 and 31.1 ± 3.2; p = 0.010 and p = 0.012), and higher DASH scores (29.3 ± 14.2 vs. 7.9 ± 9.2 and 9.5 ± 9.9; p = 0.003 and p = 0.006). Multivariate linear regression confirmed thoracic trauma as an independent predictor of higher DASH scores (β = 12.75, 95% CI: 2.00–23.50, p = 0.031, R² = 0.344). Conclusions: The MIPDS approach provides safe and effective fixation for Ideberg type Ib, II, III, IV, and V glenoid fractures with satisfactory functional outcomes at minimum 2-year follow-up. Concomitant thoracic trauma is a significant negative predictor of functional recovery, and the possibility of inferior functional outcomes in this patient group should be considered. Full article

Introduction: The management of resectable non-small cell lung cancer has long relied on a relatively limited set of determinants, primarily anatomical resectability and pathological stage. Although these parameters remain central to therapeutic planning, accumulating clinical and translational evidence indicates that they do not fully explain variability in outcomes observed after lung cancer surgery. The primary aim of this review is to evaluate whether current evidence supports the need for a novel heuristic framework in resectable NSCLC. Secondary aims are to examine how host-related, clinical, and data-driven factors contribute to prognosis and treatment selection beyond conventional staging systems. Methods: This review integrates evidence from clinical studies, national registries, and translational analyses to examine how these dimensions contribute to prognosis and treatment selection. Results: Over the past two decades, advances in surgical techniques, perioperative management, systemic therapies, and large-scale clinical databases have revealed additional determinants of prognosis beyond tumor burden, including physiological reserve, nutritional condition, systemic inflammatory state, comorbidities, and socioeconomic environment. Developments in multimodal strategies and minimally invasive surgery have reshaped the therapeutic landscape. Data-driven approaches have identified clinically meaningful subgroups not captured by conventional staging systems. Conclusions: A heuristic framework integrating tumor biology, patient characteristics, and treatment context may better reflect the complexity of contemporary thoracic oncology practice. Full article

Introduction: As multimodal therapy for esophageal cancer advances, addressing immediate and long-term functional outcomes following surgery has become more important. Despite surgical advancements, delayed gastric conduit emptying (DGCE) remains a primary cause of functional impairment after esophageal cancer resection. The literature addressing pylorus management following minimally invasive esophagectomy (MIE) is scarce. The effects of pyloric drainage with pyloromyotomy or postoperative approaches such as intrapyloric Botox injection or dilatation on the incidence and course of DGCE were the focus of this study. Methods: A retrospective analysis of consecutive patients after minimally invasive esophagectomy with thoracic esophagogastric anastomosis and gastric tube reconstruction between 2014 and 2023 was performed. Univariate analyses were used to identify significant patient-, tumor-, and procedure-related factors affecting DGCE. Results: A total of 276 patients were included. DGCE was observed in 80 (28.9%) patients. Demographics did not differ with statistical significance. Postoperative complications were not increased in patients with DGCE. Pyloric intervention (PI) did not reduce postoperative occurrence of DGCE (PI: n = 19/23.75% compared to no PI: n = 62 (30.5%), p = 0.342). Median length of hospital stay was significantly longer, and total costs were significantly higher in patients with DGCE (p = 0.03 and p = 0.047, respectively). Analysis of endoscopic approaches was not associated with a statistically significant difference between botulinum toxin injection and pyloric dilatation with regard to reinterventions. Conclusions: While DGCE is frequent after esophagectomy, it is not associated with short-term morbidity but with prolonged total hospital stay and increased costs. Intraoperative pyloric intervention does not influence the incidence of DGCE after esophagectomy and endoscopic management was associated with therapeutic success, but choice of specific, optimal approach remains elusive. Novel concepts, including preoperative dilatation should be investigated. Full article